Knights of Columbus Asset Advisors LLC Boosts Stock Position in Exact Sciences Co. (NASDAQ:EXAS)

Knights of Columbus Asset Advisors LLC grew its stake in shares of Exact Sciences Co. (NASDAQ:EXAS) by 7.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,298 shares of the medical research company’s stock after acquiring an additional 1,692 shares during the period. Knights of Columbus Asset Advisors LLC’s holdings in Exact Sciences were worth $1,309,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. Perigon Wealth Management LLC lifted its position in shares of Exact Sciences by 3.2% during the fourth quarter. Perigon Wealth Management LLC now owns 8,436 shares of the medical research company’s stock worth $474,000 after acquiring an additional 264 shares in the last quarter. Sanctuary Advisors LLC lifted its position in shares of Exact Sciences by 2.0% during the fourth quarter. Sanctuary Advisors LLC now owns 13,625 shares of the medical research company’s stock worth $763,000 after acquiring an additional 269 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in shares of Exact Sciences by 2.1% during the fourth quarter. Daiwa Securities Group Inc. now owns 14,447 shares of the medical research company’s stock worth $812,000 after acquiring an additional 300 shares in the last quarter. Advisors Asset Management Inc. lifted its position in shares of Exact Sciences by 1.4% during the third quarter. Advisors Asset Management Inc. now owns 28,650 shares of the medical research company’s stock worth $1,952,000 after acquiring an additional 402 shares in the last quarter. Finally, Intech Investment Management LLC lifted its position in shares of Exact Sciences by 3.5% during the third quarter. Intech Investment Management LLC now owns 11,986 shares of the medical research company’s stock worth $816,000 after acquiring an additional 402 shares in the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Exact Sciences Stock Performance

Exact Sciences stock opened at $45.62 on Friday. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. The firm has a 50-day moving average of $50.55 and a 200-day moving average of $58.27. The firm has a market cap of $8.47 billion, a P/E ratio of -8.19 and a beta of 1.25. Exact Sciences Co. has a 1-year low of $40.62 and a 1-year high of $79.62.

Exact Sciences (NASDAQ:EXAS) last posted its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The company had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million. Sell-side analysts expect that Exact Sciences Co. will post -0.58 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on EXAS. William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a report on Thursday, February 20th. Royal Bank of Canada began coverage on shares of Exact Sciences in a report on Thursday, March 13th. They issued a “sector perform” rating and a $52.00 price target on the stock. Barclays reduced their target price on Exact Sciences from $70.00 to $65.00 and set an “overweight” rating on the stock in a research note on Thursday, February 20th. TD Cowen increased their target price on Exact Sciences from $82.00 to $86.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Finally, BTIG Research increased their target price on Exact Sciences from $65.00 to $75.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Two research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $70.83.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.